1. Home
  2. GRF vs BMEA Comparison

GRF vs BMEA Comparison

Compare GRF & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

N/A

Current Price

$10.14

Market Cap

39.7M

Sector

Finance

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

SELL

Current Price

$0.58

Market Cap

42.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GRF
BMEA
Founded
1989
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
42.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GRF
BMEA
Price
$10.14
$0.58
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $6.17
AVG Volume (30 Days)
4.2K
★ 983.5K
Earning Date
01-01-0001
11-10-2026
Dividend Yield
★ 3.70%
N/A
EPS Growth
N/A
★ 69.19
EPS
★ 1.16
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.80
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.50
$0.45
52 Week High
$11.85
$2.24

Technical Indicators

Market Signals
Indicator
GRF
BMEA
Relative Strength Index (RSI) 49.96 38.28
Support Level $9.72 $0.55
Resistance Level $10.52 $0.69
Average True Range (ATR) 0.22 0.07
MACD 0.01 0.03
Stochastic Oscillator 19.57 48.35

Price Performance

Historical Comparison
GRF
BMEA

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: